March 18 (Reuters) - The U.S. Food and Drug Administration said on Monday it had approved UK-based Orchard Therapeutics' gene therapy for the treatment of children with a rare hereditary disease called metachromatic leukodystrophy (MLD). (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,668 JPY | 0.00% | +0.45% | +12.55% |
May. 02 | BridgeBio Pharma Shares Decline After Q1 Financial Results | MT |
Apr. 08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2,729 PTS | -0.03% | +0.66% | - | ||
2,668 JPY | 0.00% | +0.45% | 9.24B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.55% | 9.24B | |
+4.30% | 69.91B | |
-12.75% | 5.05B | |
+42.38% | 4.47B | |
+5.23% | 3.92B | |
+21.52% | 2.44B | |
-19.05% | 2.41B | |
-28.72% | 2.23B | |
+11.13% | 2.02B | |
+4.60% | 1.66B |
- Stock Market
- Equities
- 4151 Stock
- News Kyowa Kirin Co. Ltd.
- US approves first gene therapy for rare genetic disease